NCT06298032View on ClinicalTrials.gov

A Study Investigating the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Olamkicept in Healthy Persons

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

February 20, 2024

Primary Completion Date

November 15, 2024

Study Completion Date

November 15, 2024

Conditions
Inflammatory Gastrointestinal Diseases
Interventions
DRUG

Olamkicept Part A

"Intravenous infusion. Single dose.~Part A consists of 3 different doses~* 1200 mg~* 1800 mg~* 2400 mg"

DRUG

Olamkicept Part B

"Intravenous infusion. Multiple doses.~Part B consists of 3 different doses.~* 1200 mg~* 1800 mg~* 2400 mg"

DRUG

Placebo

Intravenous infusion

Trial Locations (1)

Unknown

Ferring Investigational Site, Berlin

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY